Study On The Clinical Effect Of Shuxuetongmai Jieyu Prescription On Ischemic Post-stroke Depression

Objective: To explore the clinical efficacy of Shuxuetongmai jieyu prescription in the treatment of patients with ischemic PSD,and to evaluate its safety.Methods: Sixty patients who met the ischemic PSD inclusion criteria were divided into treatment group and control group according to the random number table method,30 cases each.On the basis of basic treatment,the control group was treated with fluoxetine hydrochloride capsule,the treatment group was treated with Shuxue Tongmai Jieyu Decoction on the basis of the control group.The HAMD,PSQI,NIHSS,Barthel index scores and adverse reactions were recorded before treatment and 1 month and 3 months after treatment,and the clinical efficacy of the two groups was evaluated.Results:(1)After 3 months of treatment,the total effective rate of the treatment group was 83.33%,the total effective rate of the control group was 73.33%,the treatment group was better than the control group(P<0.05).(2)The HAMD score,NIHSS score,PQOI score and Barthel score in the two groups were significantly improved at the 1st and 3rd months after treatment(P<0.05).(3)At the 1st and 3rd months after treatment,the HAMD score,NIHSS score and PQOI score of the two groups at each time point were better than those of the control group(P<0.05).(4)There was no difference in Barthel index between the two groups at the first month after treatment(P>0.05),the improvement of Barthel index in the treatment group was better than that in the control group at the third month after treatment(P<0.05).(5)During the treatment period,there were no significant fluctuations in the safety indexes and no obvious adverse reactions of the two groups.Conclusion:Shuxuetongmai jieyu prescription can reduce the degree of depression in patients with ischemic PSD,repair neurological deficits,improve sleep quality,improve quality of life,and have a definite clinical effect.Clinical application is safe and reliable.